The first clinical pilot study of Roquinimex (Linomide®) in cancer patients with special focus on immunological effects

Cancer Investigation

Volumn 15, Issue 3, 1997, Pages 204-211

  Bergh, Jonas C S ^a   Tötterman, Thomas H ^a   Termander, Birgitta C ^b   Strandgarden, Kerstin A M P ^b   Gunnarsson, Per Olov G ^b   Nilsson, Bo I ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Pharmacia & Upjohn AB   (Sweden)

Author keywords

Clinical study; Immunological effects; Immunomodulator; Linomide; Roquinimex; Toxicity

Indexed keywords

ROQUINIMEX;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFECT; DRUG HALF LIFE; FEMALE; GROWTH INHIBITION; HUMAN; IMMUNOMODULATION; MALE; MUSCULOSKELETAL DISEASE; NAUSEA; PAIN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 1842368502     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709039716     Document Type: Article

References (19)

1. Kalland T: Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res 46:3018-3022, 1986.
2. Harnig R, Szalay J: A treatment for metastasis of murine ocular melanoma. Invest Ophthalmol Vis Sci 29:1505, 1988.
3. Stålhandske T, Kalland T: Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to bordetella pertussis in the rat. Immunopharmacology 11:87-92, 1986.
4. Tarkowski A, Gunnarsson K, Nilsson LA, Lindholm L, Stålhandske T: Successful treatment of autoimmunity in MRL/1 mice with LS 2616, a new immunomodulator. Arthritis Rheum 29(11): 1405-1409, 1986.
5. Larson EL, Joki A, Stålhandske T: Mechanism of action of the new immunomodulator LS 2616 onT-cell responses. Int J Immunopharmacol 9:425-431, 1987.
6. Kalland T, Aim G, Stålhandske T: Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol 134:3956, 1985.
7. Kalland T: Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J Immunol 144:4472-4476, 1990.
8. Bengtsson M, Simonsson B, Carlsson K, Nilsson B, Smedmyr B, Termander B, Öberg G, Tötterman, TH: Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. Transplantation 53:882-888, 1992.
9. Nilsson BI: Phase I study in malignancy of LS 2616, a new immunomodulator: methodological considerations. Cancer Detect Prev 12:553-559, 1988.
10. Rosenberg SA, Lotze MT, Muni LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lyphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889, 1987.
11. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J: Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69:1280, 1987.
12. Cregan RT, Kovach JS, Moertel CG, Frytak S, Kvols LK: A phase I trial of recombinant human tumor necrosis factor: Cancer 62:2467, 1988.
13. Woolf T, Radulovic L: Oxicams: Metabolic disposition in man and animals. Drug Metab Rev 21(2):255-276, 1989.
14. Lotzova E, Ades EW: Natural immune killer cells - Definition, heterogeneity, lytic mechanism, functions and clinical application. Highlights of the Fifth International Workshop on Natural Killer Cells, Hilton Head Island, NC. Natl Immun Cell Growth Regul 8:1-15, 1989.
15. Rosenberg SA: Immunotherapy of cancer using interleukin-2: Current status and future prospects. Immunol Today 9:58-61, 1988.
16. Herberman RB: Lymphokine-activated killer cell activity. Characteristics of effector cells and their progenitors in blood and spleen. Immunol Today 8:178-181, 1987.
17. Horowitz MM, Gale RP, Soudel PM, Goldman JM, Kersey J, Kolb HJ, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990.
18. Mantovani A: Tumor-associated macrophages. Curr Opin Immunol 2:689-692, 1990.
19. Killion JJ, Fidler U: Evasion of host responses in metastasis: Implications of cellular resistance to cytokines. Curr Opin Immunol 2:693-695, 1990.